Meeting
2022 ASCO Annual Meeting
Preliminary analysis of a phase I study of SNK01 (Autologous Non-genetically Modified Natural Killer Cells With Enhanced Cytotoxicity) monotherapy in patients with advanced solid tumors.
Authors
Victoria S. Chua-Alcala
Sarcoma Oncology Research Center, Santa Monica, CA
Victoria S. Chua-Alcala , Sant P. Chawla , Erlinda Maria Gordon , Ted T. Kim , Simranjit Sekhon , William Feske , Lucia Hui , Brenda L. Gibson , Paul Y Chang , Debra Robinson , Paul Y. Song
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination)
Clinical Trial Registration Number
NCT03941262
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2644)
DOI
10.1200/JCO.2022.40.16_suppl.2644
Abstract #
2644
Poster Bd #
298
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang
Poster
2022 ASCO Annual Meeting
The combination of CD16A/EGFR innate cell engager, AFM24, with SNK01 autologous natural killer cells in patients with advanced solid tumors.
First Author: Anthony B. El-Khoueiry
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
First Author: Iwona A. Lugowska
Poster
2023 ASCO Breakthrough
AFM24 in combination with autologous NK cells (SNK01) in patients with advanced/metastatic epidermal growth factor receptor (EGFR) expressing solid tumors: Initial results from the phase 1 dose‑escalation study.
First Author: Anthony B. El-Khoueiry